Literature DB >> 29183089

Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate.

Fady Hannah-Shmouni1, Andreas G Moraitis1,2, Vladimir Valera Romero3, Fabio R Faucz1, Spyridon A Mastroyannis1, Annabel Berthon1, Richard A Failor4, Maria Merino3, Andrew P Demidowich1, Constantine A Stratakis1.   

Abstract

Primary bilateral macronodular adrenocortical hyperplasia (PBMAH) is an uncommon cause of adrenal Cushing syndrome (CS) in which cortisol and occasionally other steroid hormones can be secreted under the influence of aberrantly expressed G-protein coupled receptors (GPCRs) in the adrenal cortex. We describe the unique case of a 64-year-old postmenopausal female with PBMAH whose adrenal lesions expressed luteinizing hormone receptors (LHr). She presented initially with CS and underwent right adrenalectomy; a few years later she presented with macromastia and mastodynia, possibly due to estrogen excess from her remaining left adrenocortical masses. Testing before and after treatment with quarterly leuprolide acetate therapy and immunohistochemistry on tissue and targeted sequencing of the genes of interest were performed. Tissue from the patient's right adrenal was tested for P450 aromatase (CYP19A1) and LHr expression; both were expressed throughout the hyperplastic cortex, although expression was more intense in the adenomatous areas. Targeted sequencing revealed a pathogenic PDE11A mutation, as well as variants in the ARMC5 and INHA genes. PDE11A expression was decreased in the adenoma but there was no loss of heterozygosity for the PDE11A locus. Because of the clinical presentation and LHr expression, quarterly leuprolide acetate therapy was started. Shortly after initiation of therapy, the patient reported decreased breast size and pain; she remains well controlled to date, after 10 years of treatment. This is the first description of a patient with PBMAH presenting with severe macromastia and mastodynia from what appears to be excess estrogen production from her adrenal tumor. The patient had a long-lasting response to chronic leuprolide acetate treatment, showing that drug therapy exploiting the aberrant receptor expression in PBMAH is possible even in the absence of cortisol overproduction. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29183089      PMCID: PMC6343127          DOI: 10.1055/s-0043-122074

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  37 in total

1.  Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome.

Authors:  A Lacroix; P Hamet; J M Boutin
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  FEMINIZING ADRENOCORTICAL TUMORS IN THE MALE. A REVIEW OF 52 CASES INCLUDING A CASE REPORT.

Authors:  J L GABRILOVE; D C SHARMA; H H WOTIZ; R I DORFMAN
Journal:  Medicine (Baltimore)       Date:  1965-01       Impact factor: 1.889

3.  Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing's syndrome features.

Authors:  Tânia L Mazzuco; Olivier Chabre; Jean-Jacques Feige; Michaël Thomas
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

4.  Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.

Authors:  S A Bovenberg; G F F M Pieters; L J Hofland; A R M M Hermus
Journal:  Neth J Med       Date:  2004-12       Impact factor: 1.422

5.  Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas.

Authors:  Karla Saner-Amigh; Bobbie A Mayhew; Franco Mantero; Francesca Schiavi; Perrin C White; Chalama V Rao; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2005-12-06       Impact factor: 5.958

Review 6.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

7.  Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease.

Authors:  C A Stratakis; N Sarlis; L S Kirschner; J A Carney; J L Doppman; L K Nieman; G P Chrousos; D A Papanicolaou
Journal:  Ann Intern Med       Date:  1999-10-19       Impact factor: 25.391

8.  Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome?

Authors:  H Mircescu; J Jilwan; N N'Diaye; I Bourdeau; J Tremblay; P Hamet; A Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

9.  Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro.

Authors:  Richard A Feelders; Steven W J Lamberts; Leo J Hofland; Peter M van Koetsveld; Miriam Verhoef-Post; Axel P N Themmen; Frank H de Jong; H Jaap Bonjer; Adrian J Clark; Aart-Jan van der Lely; Wouter W de Herder
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

10.  Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone.

Authors:  Mark O Goodarzi; David W Dawson; Xian Li; Zhenmin Lei; Peter Shintaku; Chalama V Rao; Andre J Van Herle
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

View more
  5 in total

1.  High expression of adrenal P450 aromatase (CYP19A1) in association with ARMC5-primary bilateral macronodular adrenocortical hyperplasia.

Authors:  Annabel Berthon; Fady Hannah-Shmouni; Andrea Gutierrez Maria; Fabio R Faucz; Constantine A Stratakis
Journal:  J Steroid Biochem Mol Biol       Date:  2019-04-20       Impact factor: 4.292

2.  Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia.

Authors:  Rachel Wurth; Amit Tirosh; Crystal D C Kamilaris; Jancarlos Camacho; Fabio R Faucz; Andrea Gutierrez Maria; Annabel Berthon; Georgios Z Papadakis; Naris Nilubol; Ahmed Hamimi; Ahmed M Gharib; Andrew Demidowich; Mihail Zilbermint; Graeme Eisenhofer; Leah Braun; Martin Reincke; Constantine A Stratakis; Fady Hannah-Shmouni
Journal:  J Endocr Soc       Date:  2020-10-29

3.  Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH).

Authors:  Pejman Cohan; Honey E East; Sandi-Jo Galati; Jennifer U Mercado; Precious J Lim; Michele Lamerson; James J Smith; Anne L Peters; Kevin C J Yuen
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

4.  Inhibin A as a tumor marker for primary bilateral macronodular adrenal hyperplasia.

Authors:  Rachel Wurth; Crystal Kamilaris; Naris Nilubol; Samira M Sadowski; Annabel Berthon; Martha M Quezado; Fabio R Faucz; Constantine A Stratakis; Fady Hannah-Shmouni
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-04-29

5.  A novel nonsense mutation in ARMC5 causes primary bilateral macronodular adrenocortical hyperplasia.

Authors:  Wen-Tao He; Xiong Wang; Wen Song; Xiao-Dong Song; Yan-Jun Lu; Yan-Kai Lv; Ting He; Xue-Feng Yu; Shu-Hong Hu
Journal:  BMC Med Genomics       Date:  2021-05-10       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.